Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
基本信息
- 批准号:10168710
- 负责人:
- 金额:$ 45.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-24 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
Our long-term goal is to develop a point-of-care urine test as a rapid, non-invasive surrogate for therapeutic drug
monitoring of anti-tuberculosis drugs. The overall objective of this application is to generate receiver-operating-
characteristic curves for urine colorimetry in the identification of tuberculosis patients with low anti-tuberculosis
drug exposures. The study population will include children and adults with active tuberculosis. Our central
hypothesis is that urine colorimetry will successfully identify patients with low anti-tuberculosis plasma drug
levels, and do so with diagnostic characteristics similar to other widely used tests in tuberculosis management.
The premise for this hypothesis is based on our work showing that urine colorimetry accurately identified adult
tuberculosis patients with low anti- tuberculosis plasma drug exposures. This project includes two specific aims.
In Aim 1, we will conduct a prospective, observational, intensive pharmacokinetic study of isoniazid, rifampin,
and pyrazinamide among adults treated for active tuberculosis. We will sample both blood and urine in order to
define the receiver-operating-characteristic curve for urine colorimetry to detect low anti-tuberculosis drug
exposures, as defined by the gold standard measure of plasma drug exposure (the area under the 24-hour
concentration-versus-time curve, estimated from the population pharmacokinetic model for each participant).
Because of the demonstrated value of therapeutic drug monitoring in co-morbid tuberculosis/diabetes patients,
we will stratify enrollment based on diabetes mellitus status. This stratification will support adjusted receiver-
operating-characteristic analyses of the urine colorimetric assay with diabetes as a covariate. In Aim 2, we will
determine the diagnostic characteristics of urine colorimetry to detect low plasma anti-tuberculosis drug
exposures among children and adolescents with active tuberculosis disease in a high-burden setting (Tanzania),
following a similar statistical analysis plan (pharmacokinetic analysis followed by receiver-operating-
characteristic curves for urine colorimetry). The rationale for the proposed research is that once receiver-
operating-characteristic curves for urine colorimetry are established among two key groups of high-risk
tuberculosis patients (adults with co-morbid diabetes mellitus and children), translation of these assays to a
point-of-care test can be performed. The urine colorimetric assay can then be validated as a noninvasive method
for optimizing anti-tuberculosis drug exposures in resource-limited settings.
项目总结
我们的长期目标是开发一种快速、非侵入性的治疗药物替代疗法--点尿法。
监测抗结核药物。这个应用程序的总体目标是生成接收器操作-
尿液比色法特征曲线在低抗结核患者鉴别中的应用
接触毒品。研究人群将包括患有活动性结核病的儿童和成人。我们的中央
假设尿液比色法将成功识别抗结核血浆药物含量较低的患者
水平,这样做的诊断特征类似于结核病管理中广泛使用的其他检测方法。
这一假设的前提是基于我们的工作,即尿液比色法准确识别成人
低抗结核血浆药物暴露的肺结核患者。该项目包括两个具体目标。
在目标1中,我们将进行一项前瞻性、观察性、密集的异烟肼、利福平、
在接受活动性结核病治疗的成年人中使用吡津胺。我们会同时采集血液和尿液样本,以便
确定尿液比色法检测低浓度抗结核药物的受试者-工作特性曲线
暴露,由血浆药物暴露的黄金标准衡量(24小时以下的区域
浓度-时间曲线,根据每个参与者的群体药代动力学模型估计)。
由于治疗药物监测在合并结核病/糖尿病患者中的已被证明的价值,
我们将根据糖尿病状况对注册人数进行分层。这种分层将支持调整后的接收器-
以糖尿病为协变量的尿液比色分析的操作特性分析。在目标2中,我们将
尿液比色法检测低血清抗结核药物的诊断特点
高负担环境中患有活动性结核病的儿童和青少年的暴露情况(坦桑尼亚),
遵循类似的统计分析计划(先进行药代动力学分析,然后进行接受者操作-
尿液比色法特征曲线)。拟议研究的基本原理是,一旦接收者-
在两个高危人群之间建立了尿液比色法的操作特征曲线
结核病患者(患有糖尿病的成人和儿童),将这些检测翻译成
可以执行护理点测试。然后,尿液比色分析可以被确认为一种非侵入性方法。
用于在资源有限的情况下优化抗结核药物的暴露。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Scott K Heysell其他文献
Xpert MTB/RIF Ultra assay for the detection of emMycobacterium tuberculosis/em in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, Bangladesh
在孟加拉国达卡,对于常规 Xpert MTB/RIF 检测结果为阴性但胸部影像学提示患有结核病的人群,采用 Xpert MTB/RIF Ultra 检测方法检测结核分枝杆菌的研究
- DOI:
10.1016/j.ijid.2021.11.010 - 发表时间:
2022-01-01 - 期刊:
- 影响因子:4.300
- 作者:
Samanta Biswas;Mohammad Khaja Mafij Uddin;Kishor Kumar Paul;Md. Fahim Ather;Shahriar Ahmed;Rumana Nasrin;Senjuti Kabir;Scott K Heysell;Sayera Banu - 通讯作者:
Sayera Banu
A roadmap for integrating nutritional assessment, counselling, and support into the care of people with tuberculosis
将营养评估、咨询和支持纳入结核病患者护理的路线图
- DOI:
10.1016/s2214-109x(25)00021-x - 发表时间:
2025-05-01 - 期刊:
- 影响因子:18.000
- 作者:
Pranay Sinha;Madhavi Bhargava;Madeline E Carwile;Madolyn R Dauphinais;Phumeza Tisile;Chelsie Cintron;Lindsey M Locks;Janika Hauser;Matt Oliver;Scott K Heysell;Saurabh Mehta;Julia L Finkelstein;Kobto G Koura;J Peter Cegielski;Rein M G J Houben;C Finn McQuaid;Anurag Bhargava - 通讯作者:
Anurag Bhargava
Scott K Heysell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Scott K Heysell', 18)}}的其他基金
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania
培养坦桑尼亚营养不良和结核病交叉领域的研究领导者
- 批准号:
10461564 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania
培养坦桑尼亚营养不良和结核病交叉领域的研究领导者
- 批准号:
10588197 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania
培养坦桑尼亚营养不良和结核病交叉领域的研究领导者
- 批准号:
10875013 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa
撒哈拉以南非洲地区早期经验性抗结核杆菌治疗败血症的随机临床试验
- 批准号:
10084642 - 财政年份:2020
- 资助金额:
$ 45.83万 - 项目类别:
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa
撒哈拉以南非洲地区早期经验性抗结核杆菌治疗败血症的随机临床试验
- 批准号:
10443820 - 财政年份:2020
- 资助金额:
$ 45.83万 - 项目类别:
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa
撒哈拉以南非洲地区早期经验性抗结核杆菌治疗败血症的随机临床试验
- 批准号:
10653094 - 财政年份:2020
- 资助金额:
$ 45.83万 - 项目类别:
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa
撒哈拉以南非洲地区早期经验性抗结核杆菌治疗败血症的随机临床试验
- 批准号:
10265511 - 财政年份:2020
- 资助金额:
$ 45.83万 - 项目类别:
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
10221522 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
10245319 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
10320620 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
相似海外基金
Development of the EdvoReader: a Quantitative PCR and Colorimetry Instrument for Laboratory Skills Training
EdvoReader 的开发:用于实验室技能培训的定量 PCR 和比色仪
- 批准号:
10481325 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
The EdvoReader: Developing a Quantitative PCR and Colorimetry Instrument for Laboratory Skills Training
EdvoReader:开发用于实验室技能培训的定量 PCR 和比色仪
- 批准号:
10760647 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
Development of Video Imaging Based Colorimetry Using Digital Microscope and Its Application to Flow Analysis
基于视频成像的数码显微镜比色法的开发及其在流动分析中的应用
- 批准号:
21K05127 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Contribution of Intrinsically-Photosensitive Retinal Ganglion Cells and Rods to Color Perception and Formulation of Five-Dimensional Colorimetry
本质光敏视网膜神经节细胞和视杆细胞对颜色感知的贡献和五维比色法的制定
- 批准号:
18H04111 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
10221522 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
10245319 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
10320620 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
10488657 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Colorimetry of blended phosphor powders for LED-illuminated remote phosphor plates
用于 LED 照明远程荧光板的混合荧光粉粉末的比色法
- 批准号:
524503-2018 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Collaborative Research and Development Grants
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
尿液比色法用于儿童和成人结核病药代动力学评价
- 批准号:
9789835 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别: